Study on Preserving Lean Muscle and Physical Function Using Resistance Exercise and Protein During Semaglutide or Tirzepatide Treatment for Obesity

What this Trial Is About

Researchers are evaluating whether resistance exercise and increased protein intake can help preserve lean muscle mass and improve physical function in people with obesity who are starting treatment with semaglutide or tirzepatide. The study aims to measure the impact of these interventions on muscle mass, physical function, and related health factors such as blood sugar control, liver function, and quality of life during weight loss induced by these medications. Participants will begin semaglutide or tirzepatide therapy, starting at a low dose and gradually increasing to maximize weight loss. They will be randomly assigned to one of four groups a control group maintaining usual exercise habits, a protein intake group aiming for 1.6gkgday of protein through protein drinks and diet adjustments, a resistance exercise group performing supervised exercises three times weekly, or a combined resistance exercise and protein intake group. The resistance exercise includes supervised and group sessions to ensure proper technique and progression. During the six-month study, participants will undergo various assessments including MRI scans to measure muscle and liver fat, body composition scans, muscle strength tests, and evaluations of physical activity, sleep quality, and quality of life. Blood tests will monitor blood sugar control, liver function, and inflammation markers. Researchers will track dietary intake and medication use throughout the study to understand the effects of the interventions on overall health and physical function.

LEAN Mass Preservation With Resistance Exercise and Protein During Semaglutide/Tirzepatide Therapy